Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

109.06 -3.03 (-2.70%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
43 44 Next >
Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion
The company said quarterly sales rose 2% excluding the impact of Veklury. 
Via Investor's Business Daily
Recap: Gilead Sciences Q1 Earnings
Gilead Sciences (NASDAQ:GILD) reported its Q1 earnings results on Thursday, April 28, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Gilead Sciences's Earnings Outlook
Gilead Sciences (NASDAQ:GILD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Gilead... 
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Talk Markets
Gilead's Remdesivir Becomes First Approved Treatment For Pediatric COVID-19 Patients
Via Benzinga
FDA Lifts Partial Clinical Hold On Gilead's MDS, AML Magrolimab Studies
The FDA has  
Via Benzinga
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
7 Dividend Stocks Paying Over 5% to Buy Now
Stock markets will return less this year as interest rates rise and cause a recession, so investors should demand higher yield. 
Via InvestorPlace
The Daily Biotech Pulse: WHO Endorses Pfizer's Oral COVID Therapy, Vallon Pharma Surges On Strategic Review, Novavax Starts Dosing In Adolescents COVID Booster Trial
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
WHO Backs Pfizer's Oral COVID Antiviral Therapy For High-Risk Patients
Via Benzinga
Where Gilead Sciences Stands With Analysts
Within the last quarter, Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings: 
Via Benzinga
Gilead's Yescarta Scores FDA Approval As First CAR T-Cell Therapy For Earlier Lymphoma
Via Benzinga
Pfizer: What Comes After the Covid-19 Fire?
Success with Pfizer's Covid-19 vaccine maintains the PFE stock status as a dividend aristocrat, but don't expect miracles. 
Via InvestorPlace
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
NRx Pharmaceuticals Again Requests For FDA Breakthrough Therapy Status For COVID-19 Therapy
Via Benzinga
If You Invested $1000 In Gilead Sciences 20 Years Ago, Here's How Much You Would Have Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.99% on an annualized basis producing an average annual return of 15.38%. Currently, Gilead Sciences has a market... 
Via Benzinga
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
Via InvestorPlace
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Pummeled! These 5 Dividend Growth Stocks Are Down Big Time From Their 52 Week Highs
2022 has been nuts, right? After investing for more than a decade, I've never seen this kind of sustained daily volatility before. But, as always, I see short-term volatility as a long-term... 
Via Talk Markets
Layoffs at Bluebird Bio Highlight the Current Struggles of Biotech Picks
Cash will be king in biotech picks like BLUE stock as governments slow approvals and reimbursements of new gene therapies. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 6.62% on an annualized basis producing an average annual return of 13.94%. Currently, Gilead Sciences has a market... 
Via Benzinga
10 Biggest Price Target Changes For Monday
Keybanc raised the price target on Block, Inc. (NYSE: SQ) from $175 to $180. Block shares rose 2.8% to $137.42 in pre-market trading. 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Investors Seek Second Act with Moderna Stock
MRNA stock struck gold with its Covid-19 vaccine but investors want to know if there are any other blockbusters in its pipeline. 
Via InvestorPlace
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
Via Benzinga
Ten Healthcare Companies With High Payout Ratio
The healthcare industry is among the biggest U.S. market segments in terms of market capitalization, but when it comes to dividend payouts, they rank very low. 
Via Talk Markets
10 Biggest Price Target Changes For Monday
Wells Fargo cut the price target on Gilead Sciences, Inc. (NASDAQ: GILD) from $70 to $63. Gilead Sciences shares rose 0.4% to $59.91 in pre-market trading. 
Via Benzinga
What Cramer Thinks About Hims & Hers Health, Gilead Sciences And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Healthcare Realty Trust Incorporated (NYSE: HR) as the company’s merger with Healthcare Trust of America, Inc. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
43 44 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.